Bert Hochfeld | TickerTarget Date: 2026-02-23 Quarter: Q3 FY25 (Sep-25) Stock Price: ~440|MarketCap: 36.5B | Shares: 83M diluted
I haven't covered Axon Enterprise in the newsletter, but applying my framework, this is precisely the kind of company I find intellectually stimulating -- a genuine platform compounder delivering its seventh consecutive quarter of 30%+ revenue growth while maintaining a 25% adjusted EBITDA margin. The Q3 print was a modest beat-and-raise, which is exactly the cadence you want to see from a management team employing deliberately undemanding estimates. The real story is in the leading indicators: ARR accelerated to 41% YoY while revenue grew 31%, and future contracted bookings hit $11.4 billion, up 39% YoY. That divergence -- leading indicators outrunning revenue recognition -- is among the most bullish patterns in growth investing. At approximately 13X forward EV/S on estimated 28-30% 3-year CAGR, the shares sit at the upper end of the cohort range but below where I would call them overvalued given the visibility and platform durability. After the recent 29% pullback from January highs, the risk-reward has improved materially.
The $711M revenue print beat the $705-710M guidance range modestly -- a $1-6M beat, or roughly 0.1-0.8%. This is not a blowout quarter, but in the context of Axon's guidance approach, it represents the continuation of a pattern where management sets the bar at a level they are confident of clearing. They have raised the full-year revenue guide each quarter this year: from $2.55-2.65B (initial) to $2.60-2.70B (Q1) to 2.65 − 2.73B(Q2)to 2.74B (Q3). That is the beat-and-raise cadence I look for.
What I find more compelling than the quarterly beat is the breadth of growth:
| Segment | Q3 FY25 | YoY Growth | Mix |
|---|---|---|---|
| Software & Services | $305M | +41% | 43% |
| Connected Devices | $405M | +24% | 57% |
| -- TASER | $238M | +17% | 33% |
| -- Personal Sensors | $107M | +20% | 15% |
| -- Platform Solutions | $61M | +71% | 9% |
Software & Services growing 41% while comprising 43% of revenue is the flywheel in action. This is a company that successfully pivoted from hardware to recurring software and is now accelerating the transition. Platform Solutions at +71% demonstrates that the acquired businesses (Fusus, Dedrone) are scaling within the Axon ecosystem. This is not one-segment growth -- every category is expanding.
The RPO and future contracted bookings tell the forward story. FCB at 11.4Brepresents4.2yearsofcurrentrevenuerunrate(2.74B annualized). That is an extraordinary backlog for a company growing 31%. When bookings are growing faster than revenue (39% vs. 31%), the backlog is building, not depleting. This is the leading indicator that gives me confidence in sustained 30%+ growth into FY26.
Management explicitly stated that normalized bookings (on a 5-year basis, stripping out the growing proportion of 10-year deals) are accelerating. Combined with year-to-date domestic bookings exceeding plan, the forward visibility is as strong as I've seen for any company at this scale.
The non-GAAP gross margin of 62.7% declined 50bps YoY, attributable to the first full quarter of tariff impact on the Connected Devices segment. Brittany Bagley characterized this as a "one-time adjustment" -- tariffs are now baked into the run rate, and the continued shift toward higher-margin software (S&S at 76.8% adj gross margin vs. Connected Devices at 52.1%) should resume the upward mix-shift trajectory going forward.
| Metric | Q1 FY25 | Q2 FY25 | Q3 FY25 | Direction |
|---|---|---|---|---|
| Non-GAAP Gross Margin | 63.6% | 63.3% | 62.7% | Slight compression (tariffs) |
| Adj EBITDA Margin | 25.7% | 25.7% | 24.9% | Slight compression (R&D investment) |
| S&S Adj Gross Margin | 77.7% | 78.9% | 76.8% | Stable-high |
| Connected Dev Adj GM | 52.8% | 51.1% | 52.1% | Stable |
The EBITDA margin of 24.9% is effectively on the company's 25% full-year target. Management absorbed tariffs and increased R&D spending (Vehicle Intelligence, ALPR, Workforce Mini, AI Era Plan features) while still hitting margin commitment. I want to see this 25% floor hold as the company scales new product lines. The Rule-of-55+ (31% growth + 25% EBITDA) is comfortably above the Rule of 40 benchmark that I consider the minimum threshold for quality growth companies.
The one area that requires monitoring is GAAP operating income, which has been negative for three consecutive quarters (-8.8MinQ1, −1.0M in Q2, -$2.1M in Q3). The culprit is SBC at 146Mquarterly(584M annualized), representing 20.5% of revenue. This is elevated. I would like to see SBC decline as a percentage of revenue toward the 15% range as the company scales past $3B in annual revenue. The 6.4% YoY share dilution (78M to 83M shares) is a persistent headwind to per-share value creation. Management has committed to SBC at or below 3% dilution going forward -- I will track this carefully.
This is where the thesis gets genuinely exciting:
ARR trajectory: The acceleration pattern is unmistakable.
| Quarter | ARR ($M) | YoY Growth | Net New ARR ($M) |
|---|---|---|---|
| Q1 FY25 | $1,104 | 34% | $103 |
| Q2 FY25 | $1,183 | 39% | $79 |
| Q3 FY25 | $1,252 | 41% | $69 |
ARR YoY growth accelerated from 34% to 41% across three quarters even as net new ARR showed seasonal patterns. The implication: the base is getting larger while the growth rate is accelerating. This is compounding at its finest.
NRR at 124% continues to tick upward -- from 122% a year ago to 124% now. This tells me existing customers are expanding meaningfully. The management commentary about $600+/user/month deals (several multiples of the current average) and the proliferation of 10-year contracts confirms that land-and-expand is working.
Implied ARR of $2.843B (annualizing total revenue including hardware) suggests that even including the hardware business, the overall revenue trajectory points to significant further growth from the current $2.74B FY25 guide.
The Motorola competitive question came up on the call. Josh Isner dismissed it directly: "Our customers don't see that." I would normally flag dismissiveness as a potential blind spot, but the data supports the confidence -- 85% body camera share in major US cities, 124% NRR, 10-year deals increasing, and no evidence of deal displacement in the quarter. That said, Motorola's $4.4B acquisition and SBX body camera introduction deserve continued monitoring. Competitive complacency would be a red flag; for now, the data shows no cracks.
The strategic moves are what make Axon's long-term story compelling:
Axon 911 (Prepared + Carbyne): The most significant TAM expansion in company history. Prepared showed immediate proof of concept -- 33% reduction in calls requiring human operators in one of the largest US cities within days of deployment. Carbyne brings mission-critical cloud voice infrastructure. Together, they open the 911/communications center market, which is a multi-billion dollar TAM that Axon previously had no access to. Both acquisitions are early-stage (immaterial revenue at close), which means they are investments in the future, not current revenue drivers.
Workforce Mini (Enterprise): Launch targeted mid-2026. This is Axon's play to break out of law enforcement into retail, healthcare, and logistics. Josh Isner stated, "Enterprise might be the biggest part of business." That is a bold claim, but early customer deployments of existing Axon Body 4 cameras in enterprise (with "very significant reductions in assaults on staff") support the thesis. Pent-up demand is building ahead of launch.
Dedrone / Counter-Drone: Platform Solutions grew 71% YoY. Dedrone demand spans federal, international, and state/local. The World Cup 2026 is a specific catalyst. Management described "nine figure opportunities" in the pipeline.
AI Era Plan: On pace for >10% of US state and local bookings in FY25. This is a genuine product extension, not AI-washing.
The ecosystem story is now genuinely multi-layered: body cameras + Evidence.com + Records + Fusus + Dedrone + DFR + AI Era + 911 + Enterprise. Each product creates pull-through demand for others. The CTO described the interplay as "a triangle of 911, DFR, and Real-Time Crime Centers" -- this is platform compounding.
Let me be specific about where the shares sit relative to growth cohort benchmarks.
Current valuation (at ~$440/share):
| Metric | Value |
|---|---|
| Market Cap | ~$36.5B |
| Net Cash | ~$356M |
| Enterprise Value | ~$36.1B |
| TTM Revenue | $2.56B (Q4'24 through Q3'25) |
| FY25E Revenue | $2.74B (guided) |
| EV/TTM Revenue | 14.1X |
| EV/FY25E Revenue | 13.2X |
| EV/TTM EBITDA | ~55.9X |
| Non-GAAP EPS (Q3 ann.) | ~$4.68 (Q3 $1.17 x 4) |
| Forward P/E (non-GAAP est.) | ~75-85X |
Cohort comparison: For a company with an estimated 28-30% 3-year forward revenue CAGR, the typical EV/S range in the current market is 7-14X. Axon at 13.2X forward EV/S sits at the upper end of this range. However, I would argue several factors justify a premium within the band:
The premium is not a discount, which means this is not a screaming value opportunity. But it is also not the 20X+ forward EV/S that AXON traded at historically. After the 29% pullback from January highs ($613 to $434), the risk-reward has improved meaningfully.
PEG assessment: At ~80X forward P/E on ~30% growth, the PEG is approximately 2.7X. This is elevated by my standards. However, the non-GAAP P/E is distorted by SBC; on an EBITDA basis, the story is better at ~56X TTM EBITDA growing toward 30-35% EBITDA growth.
FCF assessment: TTM FCF is approximately $370M (Q4'24 $225M + Q1'25 $1M + Q2'25 $111M + Q3'25 33M).At 36B EV, that is ~97X EV/FCF. However, Axon's FCF is highly seasonal (Q4 is consistently 50%+ of annual FCF), so annualizing based on a single quarter is misleading. On a normalized basis with $370M+ TTM FCF, the ~97X is still rich, but the trajectory is upward as revenue scales and margins hold.
My assessment: At 13X forward EV/S, Axon is at fair value to modestly rich for the growth profile. It is not cheap enough to aggressively overweight, but after the pullback, it is at a level where I can recommend holding for investors who own it and initiating a position for those who do not. The concentration limit argument applies -- this is a name where I would hold 3-5% of a high-growth portfolio, not 8-10%.
Management credibility is high. The guidance raise cadence through FY25 (four consecutive raises) demonstrates the deliberately undemanding approach I value. Patrick Smith's vision is expansive but grounded in specific product demonstrations (Prepared's 33% call reduction is not hand-waving). Brittany Bagley is disciplined on the margin commitment -- hitting 25% EBITDA despite tariffs and increased investment is execution. Josh Isner's confidence on domestic bookings ("beyond what we planned") and federal ("best federal quarter of the year") is specific rather than generic.
The only area where I flag caution is on M&A -- acquiring two early-stage companies (Prepared and Carbyne) in the same fiscal year is aggressive. Both are in a complex, regulated market (911) with potentially long sales cycles. The integration risk is manageable given the companies are small, but the 911 thesis is a multi-year bet that needs to be monitored for execution milestones.
Axon is a high-quality platform compounder with exceptional forward visibility ($11.4B contracted backlog), accelerating leading indicators (41% ARR growth), and genuine multi-year TAM expansion across three vectors. The management team has consistently delivered on commitments and employs deliberately undemanding guidance. The SBC overhang is real and prevents me from calling this a top-tier value opportunity.
After the 29% pullback, the shares are at fair value for a position of 3-5% in a high-growth portfolio. I would recommend holding for existing shareholders and initiating a modest position for those building a diversified growth portfolio. The Q4 FY25 report (Feb 24, 2026) and FY26 guidance will be the next critical catalyst -- a guide of $3.5B+ for FY26 would confirm the sustained 30% growth thesis and likely support the current valuation.
Portfolio weight: 3-5% in the high growth portfolio (not a concentration-limit name at current valuation)
Note: I haven't covered Axon in the newsletter previously, but applying my framework, the business quality is among the highest in the growth universe. The valuation is the gating factor -- at 13X forward EV/S, it's fair, not cheap.